Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 7 | 2023 | 1671 | 1.490 |
Why?
|
Heparin, Low-Molecular-Weight | 3 | 2023 | 339 | 1.310 |
Why?
|
Kidney Neoplasms | 5 | 2022 | 4262 | 1.130 |
Why?
|
Carcinoma, Renal Cell | 4 | 2022 | 3143 | 1.060 |
Why?
|
Dalteparin | 2 | 2021 | 42 | 0.990 |
Why?
|
Loperamide | 2 | 2019 | 7 | 0.820 |
Why?
|
Anticoagulants | 7 | 2023 | 4599 | 0.820 |
Why?
|
Antigens, CD19 | 4 | 2020 | 380 | 0.810 |
Why?
|
Lymphoma, B-Cell | 2 | 2019 | 931 | 0.800 |
Why?
|
Antidiarrheals | 2 | 2019 | 45 | 0.800 |
Why?
|
Immunotherapy, Adoptive | 3 | 2020 | 1270 | 0.740 |
Why?
|
Prostatic Neoplasms | 5 | 2024 | 11124 | 0.720 |
Why?
|
Antigens, CD20 | 2 | 2017 | 199 | 0.710 |
Why?
|
Thrombosis | 3 | 2023 | 2968 | 0.600 |
Why?
|
Femoral Neoplasms | 1 | 2017 | 77 | 0.600 |
Why?
|
Linitis Plastica | 1 | 2016 | 1 | 0.590 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2022 | 808 | 0.580 |
Why?
|
Hematologic Neoplasms | 3 | 2018 | 1832 | 0.580 |
Why?
|
Graft vs Tumor Effect | 1 | 2017 | 72 | 0.580 |
Why?
|
Lymphoma, T-Cell | 1 | 2019 | 299 | 0.570 |
Why?
|
Immune System Diseases | 1 | 2019 | 262 | 0.560 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2016 | 83 | 0.550 |
Why?
|
Neoplasms | 9 | 2023 | 21683 | 0.550 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2016 | 188 | 0.540 |
Why?
|
Tyrosine | 1 | 2019 | 1461 | 0.500 |
Why?
|
Acute Coronary Syndrome | 4 | 2018 | 2337 | 0.500 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2022 | 5442 | 0.500 |
Why?
|
Bed Rest | 1 | 2014 | 84 | 0.490 |
Why?
|
Lesch-Nyhan Syndrome | 1 | 2014 | 14 | 0.490 |
Why?
|
Dermatitis | 1 | 2016 | 197 | 0.480 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2022 | 2245 | 0.480 |
Why?
|
Radiculopathy | 1 | 2016 | 197 | 0.470 |
Why?
|
Randomized Controlled Trials as Topic | 15 | 2022 | 9959 | 0.460 |
Why?
|
Physicians, Women | 1 | 2020 | 486 | 0.460 |
Why?
|
Nephrectomy | 1 | 2019 | 1050 | 0.450 |
Why?
|
Review Literature as Topic | 1 | 2015 | 336 | 0.450 |
Why?
|
Vitamin K 2 | 1 | 2012 | 47 | 0.440 |
Why?
|
Renal Artery Obstruction | 1 | 2014 | 248 | 0.440 |
Why?
|
Spinal Stenosis | 1 | 2016 | 255 | 0.440 |
Why?
|
Government | 1 | 2013 | 165 | 0.430 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 501 | 0.420 |
Why?
|
Arrhythmias, Cardiac | 3 | 2019 | 2268 | 0.410 |
Why?
|
Recombinant Fusion Proteins | 2 | 2017 | 3772 | 0.400 |
Why?
|
Hemorrhage | 9 | 2023 | 3461 | 0.400 |
Why?
|
Humans | 105 | 2024 | 744343 | 0.400 |
Why?
|
Access to Information | 2 | 2016 | 320 | 0.400 |
Why?
|
Coronary Occlusion | 1 | 2014 | 304 | 0.380 |
Why?
|
T-Lymphocytes | 3 | 2017 | 10180 | 0.380 |
Why?
|
Consumer Health Information | 1 | 2013 | 211 | 0.380 |
Why?
|
Foramen Ovale, Patent | 1 | 2013 | 223 | 0.380 |
Why?
|
Human Rights | 1 | 2013 | 307 | 0.380 |
Why?
|
Meta-Analysis as Topic | 1 | 2015 | 1344 | 0.370 |
Why?
|
Multiple Myeloma | 4 | 2022 | 5181 | 0.370 |
Why?
|
Troponin | 1 | 2014 | 524 | 0.360 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2021 | 2214 | 0.350 |
Why?
|
Liver Neoplasms | 4 | 2022 | 4253 | 0.340 |
Why?
|
Blood Coagulation | 1 | 2014 | 1127 | 0.320 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2019 | 3508 | 0.320 |
Why?
|
Thromboembolism | 1 | 2014 | 986 | 0.320 |
Why?
|
Cardiovascular Agents | 1 | 2014 | 850 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 11524 | 0.300 |
Why?
|
Vitamins | 2 | 2014 | 1622 | 0.300 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2017 | 2540 | 0.300 |
Why?
|
Syncope | 3 | 2015 | 429 | 0.300 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1333 | 0.290 |
Why?
|
B-Lymphocytes | 2 | 2017 | 4665 | 0.290 |
Why?
|
Chest Pain | 1 | 2014 | 1114 | 0.290 |
Why?
|
Myocarditis | 1 | 2014 | 771 | 0.280 |
Why?
|
Minority Groups | 3 | 2023 | 1223 | 0.270 |
Why?
|
Death, Sudden, Cardiac | 1 | 2014 | 1541 | 0.270 |
Why?
|
Coronary Thrombosis | 3 | 2018 | 495 | 0.260 |
Why?
|
Interleukin-12 | 2 | 2018 | 579 | 0.260 |
Why?
|
Androgen Antagonists | 3 | 2023 | 1377 | 0.260 |
Why?
|
Vascular Surgical Procedures | 1 | 2014 | 1475 | 0.260 |
Why?
|
Arthritis, Psoriatic | 2 | 2018 | 215 | 0.260 |
Why?
|
Cisplatin | 2 | 2022 | 1662 | 0.250 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1596 | 0.250 |
Why?
|
Recurrence | 6 | 2022 | 8340 | 0.250 |
Why?
|
Transplantation, Autologous | 5 | 2022 | 2124 | 0.250 |
Why?
|
Defibrillators, Implantable | 1 | 2014 | 1440 | 0.250 |
Why?
|
Anticholesteremic Agents | 2 | 2022 | 979 | 0.250 |
Why?
|
Male | 37 | 2024 | 350118 | 0.250 |
Why?
|
Pyridones | 2 | 2020 | 712 | 0.240 |
Why?
|
Graft vs Host Disease | 1 | 2017 | 2957 | 0.240 |
Why?
|
Administration, Oral | 3 | 2021 | 3913 | 0.240 |
Why?
|
Disease-Free Survival | 3 | 2022 | 6895 | 0.230 |
Why?
|
Stroke | 6 | 2022 | 9981 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 9239 | 0.230 |
Why?
|
Castration | 1 | 2023 | 159 | 0.230 |
Why?
|
Myocardial Infarction | 5 | 2022 | 11727 | 0.220 |
Why?
|
Cardiovascular Diseases | 8 | 2022 | 15165 | 0.210 |
Why?
|
Treatment Outcome | 20 | 2022 | 63114 | 0.210 |
Why?
|
Influenza Vaccines | 2 | 2020 | 738 | 0.210 |
Why?
|
Interleukin-17 | 2 | 2018 | 899 | 0.200 |
Why?
|
Chronic Disease | 1 | 2016 | 9146 | 0.200 |
Why?
|
Warfarin | 2 | 2023 | 1496 | 0.200 |
Why?
|
Chemoprevention | 2 | 2014 | 319 | 0.200 |
Why?
|
Stroke Volume | 1 | 2014 | 5007 | 0.200 |
Why?
|
Waiting Lists | 4 | 2019 | 692 | 0.200 |
Why?
|
Liver Transplantation | 3 | 2019 | 2119 | 0.190 |
Why?
|
Aged | 20 | 2023 | 163280 | 0.190 |
Why?
|
Antihypertensive Agents | 3 | 2015 | 2046 | 0.190 |
Why?
|
Transplantation, Homologous | 3 | 2018 | 4776 | 0.180 |
Why?
|
Clinical Trials as Topic | 5 | 2017 | 7913 | 0.180 |
Why?
|
Risk Assessment | 9 | 2021 | 23338 | 0.180 |
Why?
|
Tissue Donors | 3 | 2019 | 2240 | 0.180 |
Why?
|
Psoriasis | 2 | 2018 | 898 | 0.180 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2021 | 153 | 0.180 |
Why?
|
Deoxycytidine | 2 | 2022 | 826 | 0.180 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 1519 | 0.170 |
Why?
|
IgA Deficiency | 1 | 2019 | 43 | 0.170 |
Why?
|
Muscles | 2 | 2022 | 1614 | 0.170 |
Why?
|
Vinblastine | 1 | 2020 | 502 | 0.170 |
Why?
|
Pyrazoles | 2 | 2020 | 1972 | 0.160 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.160 |
Why?
|
Hot Temperature | 2 | 2014 | 1354 | 0.160 |
Why?
|
Adiposis Dolorosa | 1 | 2018 | 12 | 0.160 |
Why?
|
Atherosclerosis | 1 | 2014 | 3445 | 0.160 |
Why?
|
Artificial Intelligence | 2 | 2021 | 2214 | 0.160 |
Why?
|
Azotemia | 1 | 2017 | 8 | 0.160 |
Why?
|
Remission Induction | 3 | 2020 | 2386 | 0.160 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2020 | 1634 | 0.150 |
Why?
|
Coronary Artery Disease | 2 | 2016 | 6487 | 0.150 |
Why?
|
Dermatologic Agents | 2 | 2019 | 278 | 0.150 |
Why?
|
Bibliometrics | 2 | 2018 | 339 | 0.150 |
Why?
|
Receptors, Antigen | 1 | 2017 | 53 | 0.150 |
Why?
|
Natural Language Processing | 2 | 2022 | 1041 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3255 | 0.150 |
Why?
|
Antiviral Agents | 2 | 2020 | 2987 | 0.140 |
Why?
|
IgG Deficiency | 1 | 2016 | 28 | 0.140 |
Why?
|
Interleukin-23 | 1 | 2018 | 193 | 0.140 |
Why?
|
Amphetamine | 1 | 2018 | 225 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 2019 | 389 | 0.140 |
Why?
|
Pulmonary Embolism | 2 | 2021 | 2376 | 0.140 |
Why?
|
Female | 26 | 2023 | 380194 | 0.140 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 379 | 0.140 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 131 | 0.140 |
Why?
|
Desert Climate | 1 | 2015 | 14 | 0.130 |
Why?
|
Back Pain | 1 | 2020 | 545 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 4 | 2016 | 35421 | 0.130 |
Why?
|
Health Expenditures | 2 | 2020 | 2348 | 0.130 |
Why?
|
Androgens | 1 | 2023 | 1281 | 0.130 |
Why?
|
Immobility Response, Tonic | 1 | 2014 | 14 | 0.130 |
Why?
|
Survival Analysis | 5 | 2020 | 10252 | 0.130 |
Why?
|
Retrospective Studies | 12 | 2023 | 77449 | 0.130 |
Why?
|
Antigens, Differentiation | 1 | 2018 | 927 | 0.130 |
Why?
|
Prodrugs | 1 | 2017 | 268 | 0.130 |
Why?
|
Interleukins | 1 | 2019 | 791 | 0.130 |
Why?
|
Physical Examination | 1 | 2021 | 1237 | 0.130 |
Why?
|
Hypercalcemia | 1 | 2017 | 409 | 0.120 |
Why?
|
Middle Aged | 20 | 2023 | 213383 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2021 | 1783 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5535 | 0.120 |
Why?
|
Sternum | 1 | 2015 | 177 | 0.120 |
Why?
|
Hepatitis B virus | 1 | 2018 | 513 | 0.120 |
Why?
|
Avitaminosis | 1 | 2014 | 34 | 0.120 |
Why?
|
Sternotomy | 1 | 2015 | 121 | 0.120 |
Why?
|
Injections, Epidural | 1 | 2016 | 195 | 0.120 |
Why?
|
Breast | 1 | 2023 | 1969 | 0.120 |
Why?
|
Aspirin | 2 | 2016 | 3282 | 0.120 |
Why?
|
Dietary Supplements | 2 | 2019 | 3297 | 0.120 |
Why?
|
Antibodies, Bispecific | 1 | 2016 | 164 | 0.120 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11031 | 0.120 |
Why?
|
Financial Management | 1 | 2015 | 160 | 0.120 |
Why?
|
Fractures, Ununited | 1 | 2015 | 165 | 0.120 |
Why?
|
Doxorubicin | 1 | 2020 | 2234 | 0.120 |
Why?
|
United States | 11 | 2022 | 69872 | 0.120 |
Why?
|
Methotrexate | 1 | 2020 | 1727 | 0.120 |
Why?
|
Prognosis | 4 | 2024 | 29063 | 0.120 |
Why?
|
Abdominal Fat | 1 | 2015 | 223 | 0.120 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 12959 | 0.120 |
Why?
|
Internal Medicine | 1 | 2020 | 1009 | 0.110 |
Why?
|
Hashimoto Disease | 1 | 2014 | 97 | 0.110 |
Why?
|
Propensity Score | 2 | 2018 | 1781 | 0.110 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2014 | 86 | 0.110 |
Why?
|
Cell Count | 1 | 2017 | 1856 | 0.110 |
Why?
|
Antibodies, Monoclonal | 3 | 2019 | 9274 | 0.110 |
Why?
|
Arthralgia | 1 | 2017 | 456 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5221 | 0.110 |
Why?
|
Amnion | 1 | 2014 | 209 | 0.110 |
Why?
|
Photosensitizing Agents | 1 | 2017 | 602 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8642 | 0.110 |
Why?
|
Rheumatic Diseases | 1 | 2019 | 592 | 0.110 |
Why?
|
Liver Failure | 1 | 2015 | 241 | 0.110 |
Why?
|
Salvage Therapy | 2 | 2017 | 1275 | 0.110 |
Why?
|
Antirheumatic Agents | 2 | 2019 | 1339 | 0.110 |
Why?
|
Endosonography | 1 | 2016 | 610 | 0.110 |
Why?
|
Publishing | 1 | 2020 | 833 | 0.110 |
Why?
|
Hepatitis B | 1 | 2018 | 695 | 0.110 |
Why?
|
Oligopeptides | 1 | 2018 | 1189 | 0.110 |
Why?
|
Biomedical Research | 2 | 2020 | 3309 | 0.110 |
Why?
|
Hepatic Encephalopathy | 1 | 2013 | 139 | 0.100 |
Why?
|
Seasons | 2 | 2015 | 1493 | 0.100 |
Why?
|
Hypotension, Orthostatic | 1 | 2015 | 255 | 0.100 |
Why?
|
Brachytherapy | 1 | 2020 | 1248 | 0.100 |
Why?
|
Drug Resistance | 1 | 2018 | 1609 | 0.100 |
Why?
|
Drug Administration Schedule | 5 | 2018 | 4933 | 0.100 |
Why?
|
Fatty Liver | 1 | 2018 | 727 | 0.100 |
Why?
|
Periodicals as Topic | 3 | 2020 | 1432 | 0.100 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2016 | 652 | 0.100 |
Why?
|
Receptors, Immunologic | 1 | 2018 | 1423 | 0.100 |
Why?
|
Bioprosthesis | 1 | 2016 | 596 | 0.100 |
Why?
|
Fibrinolytic Agents | 1 | 2021 | 2158 | 0.100 |
Why?
|
Faculty, Medical | 1 | 2020 | 1181 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 934 | 0.100 |
Why?
|
Pancreatic Neoplasms | 2 | 2020 | 5256 | 0.100 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3616 | 0.100 |
Why?
|
Drug-Eluting Stents | 2 | 2015 | 753 | 0.100 |
Why?
|
Research Support as Topic | 1 | 2015 | 705 | 0.100 |
Why?
|
Photochemotherapy | 1 | 2017 | 807 | 0.100 |
Why?
|
Conflict of Interest | 1 | 2015 | 544 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3479 | 0.090 |
Why?
|
End Stage Liver Disease | 1 | 2015 | 314 | 0.090 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2013 | 478 | 0.090 |
Why?
|
Endometrial Neoplasms | 1 | 2020 | 1353 | 0.090 |
Why?
|
Leadership | 1 | 2020 | 1357 | 0.090 |
Why?
|
Cardiac Surgical Procedures | 2 | 2016 | 3537 | 0.090 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2016 | 868 | 0.090 |
Why?
|
Hypertension | 3 | 2015 | 8480 | 0.090 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2015 | 496 | 0.090 |
Why?
|
Tissue and Organ Procurement | 2 | 2015 | 896 | 0.090 |
Why?
|
Pacemaker, Artificial | 1 | 2015 | 816 | 0.090 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2016 | 964 | 0.090 |
Why?
|
Sex Characteristics | 1 | 2020 | 2585 | 0.090 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2569 | 0.080 |
Why?
|
Education, Medical | 1 | 2021 | 1721 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1956 | 0.080 |
Why?
|
Morbidity | 1 | 2014 | 1769 | 0.080 |
Why?
|
Lymphatic Metastasis | 1 | 2016 | 2924 | 0.080 |
Why?
|
Skin Diseases | 1 | 2017 | 1065 | 0.080 |
Why?
|
Knee Joint | 1 | 2017 | 1680 | 0.080 |
Why?
|
Cicatrix | 1 | 2014 | 764 | 0.080 |
Why?
|
Dermatology | 1 | 2018 | 872 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2018 | 3068 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2016 | 1381 | 0.080 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2017 | 1444 | 0.080 |
Why?
|
Heart Valve Diseases | 1 | 2016 | 1073 | 0.080 |
Why?
|
Lymphoma | 1 | 2017 | 1877 | 0.080 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6234 | 0.080 |
Why?
|
Interleukin-6 | 1 | 2018 | 3200 | 0.080 |
Why?
|
Journal Impact Factor | 2 | 2020 | 156 | 0.080 |
Why?
|
Secondary Prevention | 1 | 2014 | 1530 | 0.080 |
Why?
|
Survivors | 1 | 2018 | 2291 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13102 | 0.070 |
Why?
|
Immunotherapy | 2 | 2020 | 4445 | 0.070 |
Why?
|
Heart Valve Prosthesis | 1 | 2016 | 1488 | 0.070 |
Why?
|
Heparin | 1 | 2014 | 1637 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12354 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 1855 | 0.070 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2016 | 1265 | 0.070 |
Why?
|
Bone Marrow | 1 | 2017 | 2948 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2012 | 2971 | 0.070 |
Why?
|
Lumbar Vertebrae | 1 | 2016 | 1848 | 0.070 |
Why?
|
Adult | 15 | 2022 | 214055 | 0.070 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2014 | 980 | 0.070 |
Why?
|
Health Behavior | 1 | 2018 | 2636 | 0.070 |
Why?
|
Aortic Valve | 1 | 2016 | 1922 | 0.070 |
Why?
|
Diabetes Complications | 1 | 2013 | 1359 | 0.070 |
Why?
|
Primary Health Care | 2 | 2020 | 4558 | 0.070 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2016 | 1536 | 0.070 |
Why?
|
Biopsy | 1 | 2017 | 6756 | 0.070 |
Why?
|
Clinical Competence | 1 | 2021 | 4687 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2023 | 20822 | 0.060 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13695 | 0.060 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 25043 | 0.060 |
Why?
|
Disabled Persons | 1 | 2014 | 1212 | 0.060 |
Why?
|
Organ Transplantation | 1 | 2015 | 1139 | 0.060 |
Why?
|
Coronary Vessels | 1 | 2015 | 3107 | 0.060 |
Why?
|
Animals | 7 | 2018 | 168757 | 0.060 |
Why?
|
Antipsychotic Agents | 1 | 2017 | 3057 | 0.060 |
Why?
|
Stents | 1 | 2015 | 3280 | 0.060 |
Why?
|
Acute Disease | 1 | 2014 | 7149 | 0.060 |
Why?
|
Tomography, Optical Coherence | 1 | 2015 | 2657 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2013 | 1863 | 0.060 |
Why?
|
Risk Factors | 10 | 2022 | 72290 | 0.050 |
Why?
|
Myocardium | 1 | 2016 | 4776 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2020 | 57776 | 0.050 |
Why?
|
Electric Power Supplies | 1 | 2023 | 99 | 0.050 |
Why?
|
Cholesterol, LDL | 2 | 2022 | 2356 | 0.050 |
Why?
|
Healthcare Disparities | 2 | 2015 | 3158 | 0.050 |
Why?
|
Young Adult | 6 | 2020 | 56430 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2018 | 21746 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Comorbidity | 1 | 2016 | 10388 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Liver | 1 | 2018 | 7474 | 0.050 |
Why?
|
Pain | 1 | 2017 | 4986 | 0.050 |
Why?
|
Electrocardiography | 1 | 2015 | 6442 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 12804 | 0.050 |
Why?
|
Palliative Care | 1 | 2016 | 3493 | 0.050 |
Why?
|
Time Factors | 6 | 2019 | 40075 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2021 | 97 | 0.050 |
Why?
|
Depression | 1 | 2020 | 7766 | 0.050 |
Why?
|
Bipolar Disorder | 1 | 2017 | 5027 | 0.050 |
Why?
|
Databases, Factual | 3 | 2020 | 7729 | 0.040 |
Why?
|
Minnesota | 1 | 2020 | 344 | 0.040 |
Why?
|
Spondylosis | 1 | 2020 | 81 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8089 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 528 | 0.040 |
Why?
|
Prosthesis Design | 2 | 2016 | 2110 | 0.040 |
Why?
|
Stem Cell Transplantation | 2 | 2019 | 1620 | 0.040 |
Why?
|
Substance-Related Disorders | 1 | 2015 | 4258 | 0.040 |
Why?
|
Ritonavir | 1 | 2020 | 322 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 275 | 0.040 |
Why?
|
Catheters | 1 | 2021 | 425 | 0.040 |
Why?
|
Mastectomy, Segmental | 1 | 2023 | 956 | 0.040 |
Why?
|
Aromatase Inhibitors | 1 | 2022 | 491 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2023 | 1770 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 890 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2018 | 199 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17446 | 0.040 |
Why?
|
Hormones | 1 | 2021 | 889 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15076 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7279 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39050 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 841 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2021 | 1097 | 0.040 |
Why?
|
Keratosis, Actinic | 1 | 2017 | 74 | 0.040 |
Why?
|
Information Storage and Retrieval | 1 | 2022 | 824 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 412 | 0.040 |
Why?
|
Standard of Care | 1 | 2020 | 564 | 0.030 |
Why?
|
Patient Care | 1 | 2022 | 640 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2018 | 2727 | 0.030 |
Why?
|
Electronic Health Records | 2 | 2023 | 4468 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 2014 | 5034 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 973 | 0.030 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3610 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 610 | 0.030 |
Why?
|
Arizona | 1 | 2015 | 108 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2021 | 1142 | 0.030 |
Why?
|
Fractures, Comminuted | 1 | 2015 | 52 | 0.030 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 161 | 0.030 |
Why?
|
Anesthesia, Local | 1 | 2017 | 275 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 1959 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2022 | 1130 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23403 | 0.030 |
Why?
|
Patient Care Management | 1 | 2018 | 306 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2019 | 494 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5751 | 0.030 |
Why?
|
China | 1 | 2020 | 2248 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2019 | 847 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2017 | 675 | 0.030 |
Why?
|
Odds Ratio | 2 | 2016 | 9849 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 426 | 0.030 |
Why?
|
Dehydration | 1 | 2015 | 234 | 0.030 |
Why?
|
Indoles | 1 | 2022 | 1839 | 0.030 |
Why?
|
Prednisolone | 1 | 2014 | 334 | 0.030 |
Why?
|
Azathioprine | 1 | 2014 | 353 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2309 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12245 | 0.030 |
Why?
|
Thalidomide | 1 | 2018 | 890 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2018 | 5172 | 0.030 |
Why?
|
Geography | 1 | 2015 | 669 | 0.030 |
Why?
|
Fracture Healing | 1 | 2015 | 427 | 0.030 |
Why?
|
History, 21st Century | 1 | 2018 | 1534 | 0.030 |
Why?
|
Phagocytosis | 1 | 2018 | 1539 | 0.030 |
Why?
|
Bone Plates | 1 | 2015 | 468 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2021 | 1177 | 0.030 |
Why?
|
Glomerulonephritis | 1 | 2014 | 372 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2014 | 15295 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2416 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 2021 | 2161 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2021 | 1861 | 0.030 |
Why?
|
Carcinoma, Basal Cell | 1 | 2017 | 545 | 0.030 |
Why?
|
Incidence | 2 | 2020 | 20947 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15540 | 0.020 |
Why?
|
Metals | 1 | 2015 | 719 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 2728 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2018 | 2539 | 0.020 |
Why?
|
Cohort Studies | 1 | 2013 | 40561 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2020 | 2107 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2948 | 0.020 |
Why?
|
Nerve Block | 1 | 2017 | 644 | 0.020 |
Why?
|
Long QT Syndrome | 1 | 2015 | 453 | 0.020 |
Why?
|
Dexamethasone | 1 | 2018 | 1951 | 0.020 |
Why?
|
Thyroxine | 1 | 2014 | 667 | 0.020 |
Why?
|
History, 20th Century | 1 | 2018 | 2740 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2016 | 935 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2015 | 1850 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 2017 | 1598 | 0.020 |
Why?
|
Prevalence | 2 | 2020 | 15226 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1859 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3508 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2022 | 3597 | 0.020 |
Why?
|
Cholesterol | 1 | 2018 | 2917 | 0.020 |
Why?
|
Perioperative Care | 1 | 2016 | 1002 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3584 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2242 | 0.020 |
Why?
|
Echocardiography | 1 | 2021 | 5102 | 0.020 |
Why?
|
Information Dissemination | 1 | 2016 | 1099 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 12026 | 0.020 |
Why?
|
Curriculum | 1 | 2021 | 3605 | 0.020 |
Why?
|
Pain Measurement | 1 | 2017 | 3420 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3278 | 0.020 |
Why?
|
Equipment Design | 1 | 2015 | 3582 | 0.020 |
Why?
|
Venous Thrombosis | 1 | 2016 | 1239 | 0.020 |
Why?
|
Surgical Flaps | 1 | 2015 | 1640 | 0.020 |
Why?
|
Disease Progression | 1 | 2023 | 13284 | 0.020 |
Why?
|
Coronary Artery Bypass | 1 | 2015 | 2289 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5720 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12788 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10943 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5524 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2018 | 3966 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5952 | 0.020 |
Why?
|
Coronary Disease | 1 | 2019 | 6077 | 0.020 |
Why?
|
Wound Healing | 1 | 2015 | 2785 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3022 | 0.020 |
Why?
|
Logistic Models | 1 | 2018 | 13408 | 0.010 |
Why?
|
Apoptosis | 1 | 2018 | 9727 | 0.010 |
Why?
|
Exercise | 1 | 2018 | 5615 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4034 | 0.010 |
Why?
|
Smoking | 1 | 2018 | 8987 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 12720 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Diet | 1 | 2018 | 7939 | 0.010 |
Why?
|
Adolescent | 2 | 2020 | 85781 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19905 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29786 | 0.010 |
Why?
|
Age Factors | 1 | 2013 | 18370 | 0.010 |
Why?
|
Aging | 1 | 2014 | 8664 | 0.010 |
Why?
|
Inflammation | 1 | 2014 | 10638 | 0.010 |
Why?
|